🚀 VC round data is live in beta, check it out!
BridgeBio Oncology Valuation Multiples
Discover revenue and EBITDA valuation multiples for BridgeBio Oncology and similar public comparables like Polaris Group, MapLight Therapeutics, KalVista Pharmaceuticals, Agomab Therapeutics and more.
BridgeBio Oncology Overview
About BridgeBio Oncology
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.
Founded
2016
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$335M
BridgeBio Oncology Financials
BridgeBio Oncology reported last 12-month revenue of — and negative EBITDA of ($154M).
In the same LTM period, BridgeBio Oncology generated — in gross profit, ($154M) in EBITDA losses, and had net loss of ($151M).
BridgeBio Oncology P&L
In the most recent fiscal year, BridgeBio Oncology reported revenue of — and EBITDA of ($143M).
BridgeBio Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($154M) | XXX | ($143M) | XXX | XXX | XXX |
| Net Profit | ($151M) | XXX | ($134M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BridgeBio Oncology Stock Performance
BridgeBio Oncology has current market cap of $800M, and enterprise value of $335M.
BridgeBio Oncology's stock price is $10.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $335M | $800M | 0.0% | XXX | XXX | XXX | $-1.68 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBridgeBio Oncology Valuation Multiples
BridgeBio Oncology trades at (2.2x) EV/EBITDA.
BridgeBio Oncology Financial Valuation Multiples
As of March 29, 2026, BridgeBio Oncology has market cap of $800M and EV of $335M.
Equity research analysts estimate BridgeBio Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BridgeBio Oncology has a P/E ratio of (5.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $800M | XXX | $800M | XXX | XXX | XXX |
| EV (current) | $335M | XXX | $335M | XXX | XXX | XXX |
| EV/EBITDA | (2.2x) | XXX | (2.3x) | XXX | XXX | XXX |
| EV/EBIT | (1.9x) | XXX | (2.3x) | XXX | XXX | XXX |
| P/E | (5.3x) | XXX | (6.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BridgeBio Oncology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BridgeBio Oncology Margins & Growth Rates
BridgeBio Oncology's revenue in the last fiscal year grew by —.
BridgeBio Oncology Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 26% | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BridgeBio Oncology Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Polaris Group | XXX | XXX | XXX | XXX | XXX | XXX |
| MapLight Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| KalVista Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Agomab Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Nika Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BridgeBio Oncology M&A Activity
BridgeBio Oncology acquired XXX companies to date.
Last acquisition by BridgeBio Oncology was on XXXXXXXX, XXXXX. BridgeBio Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BridgeBio Oncology
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBridgeBio Oncology Investment Activity
BridgeBio Oncology invested in XXX companies to date.
BridgeBio Oncology made its latest investment on XXXXXXXX, XXXXX. BridgeBio Oncology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BridgeBio Oncology
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BridgeBio Oncology
| When was BridgeBio Oncology founded? | BridgeBio Oncology was founded in 2016. |
| Where is BridgeBio Oncology headquartered? | BridgeBio Oncology is headquartered in United States. |
| Is BridgeBio Oncology publicly listed? | Yes, BridgeBio Oncology is a public company listed on Nasdaq. |
| What is the stock symbol of BridgeBio Oncology? | BridgeBio Oncology trades under BBOT ticker. |
| When did BridgeBio Oncology go public? | BridgeBio Oncology went public in 2025. |
| Who are competitors of BridgeBio Oncology? | BridgeBio Oncology main competitors are Polaris Group, MapLight Therapeutics, KalVista Pharmaceuticals, Agomab Therapeutics. |
| What is the current market cap of BridgeBio Oncology? | BridgeBio Oncology's current market cap is $800M. |
| Is BridgeBio Oncology profitable? | No, BridgeBio Oncology is not profitable. |
| What is the current EBITDA of BridgeBio Oncology? | BridgeBio Oncology has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of BridgeBio Oncology? | Current EBITDA multiple of BridgeBio Oncology is (2.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.